Muderrisoglu Ahmet, Babaoglu Elif, Korkmaz Elif Tugce, Kalkisim Said, Karabulut Erdem, Emri Salih, Babaoglu Melih O
Department of Pharmacology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Department of Chest Diseases, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Front Genet. 2022 Feb 10;13:812715. doi: 10.3389/fgene.2022.812715. eCollection 2022.
To investigate the effects of genetic polymorphisms of human nicotinic acetylcholine receptor subunits α3, α4 and α5, which are encoded by , genes, respectively, on nicotine addiction and outcomes of pharmacological treatments for smoking cessation. A total of 143 smokers and 130 non-smokers were included. Genotyping for polymorphisms was performed by PCR, flowed by RFLP. Clinical outcomes and success rates of pharmacological treatments for smoking cessation with nicotine replacement therapy (NRT), bupropion or varenicline were determined at the 12th week of the treatment. Overall, 52 out of 143 (36.4%) smokers who received pharmacotherapy were able to quit smoking. Success rates for smoking cessation were similar for female (30.3%) and male (41.6%) subjects ( = 0.16). The success rate for smoking cessation treatment with varenicline (58.5%) was significantly higher as compared to other treatments with NRT (20.0%), bupropion (32.3%) or bupropion + NRT (40.0%) (chi-square test, = 0.001). Smoker . non-smoker status and the clinical outcomes of drugs used for smoking cessation were found similar in subjects carrying wild-type and variant alleles of human nicotinic acetylcholine receptor α subunits. In this study, smoking cessation treatment with varenicline was significantly more effective than treatments with nicotine replacement or bupropion in a cohort of Turkish subjects. Smoker/non-smoker status and the clinical outcomes of treatment with pharmacological agents were similar in subjects with wild-type or variant alleles for human nicotinic acetylcholine receptor subunits α3 (), α4 () and α5 ().
为研究分别由 、 、 基因编码的人类烟碱型乙酰胆碱受体亚基α3、α4和α5的基因多态性对尼古丁成瘾及戒烟药物治疗效果的影响。共纳入143名吸烟者和130名非吸烟者。采用聚合酶链反应（PCR）对 多态性进行基因分型，随后进行限制性片段长度多态性分析（RFLP）。在治疗第12周时确定使用尼古丁替代疗法（NRT）、安非他酮或伐尼克兰进行戒烟药物治疗的临床结局和成功率。总体而言，143名接受药物治疗的吸烟者中有52名（36.4%）成功戒烟。女性（30.3%）和男性（41.6%）受试者的戒烟成功率相似（ = 0.16）。与其他治疗方法（NRT为20.0%、安非他酮为32.3%或安非他酮+NRT为40.0%）相比，伐尼克兰戒烟治疗的成功率（58.5%）显著更高（卡方检验， = 0.001）。在携带人类烟碱型乙酰胆碱受体α亚基野生型和变异等位基因的受试者中，吸烟者/非吸烟者状态及用于戒烟的药物临床结局相似。在本研究的一组土耳其受试者中，伐尼克兰戒烟治疗比尼古丁替代或安非他酮治疗显著更有效。对于人类烟碱型乙酰胆碱受体亚基α3（）α4（）和α5（）具有野生型或变异等位基因的受试者，吸烟者/非吸烟者状态及药物治疗的临床结局相似。
